

KERYX BIOPHARMACEUTICALS INC

Form 8-K

February 22, 2006

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **February 15, 2006**

Keryx Biopharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

000-30929
(Commission File Number)

13-4087132
(IRS Employer Identification No.)

750 Lexington Avenue
New York, New York 10022
(Address of Principal Executive Offices)

(212) 531-5965
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- | | |
|--------------------------|---|
| <input type="checkbox"/> | Written communications pursuant to Rule 425 under the Securities Act. |
| <input type="checkbox"/> | Soliciting material pursuant to Rule 14a-12 under the Exchange Act. |
| <input type="checkbox"/> | Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act. |
| <input type="checkbox"/> | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. |
-
-
-

Item 8.01. Other Events.

On February 15, 2006, Keryx Biopharmaceuticals, Inc. ("Keryx") issued a press release announcing that Keryx entered into a License Agreement (the "Agreement") with Panion & BF Biotech, Inc. ("Panion"), a drug development company based in Taiwan that holds the rights to ZerenexTM, an oral, inorganic, iron-based compound that has the capacity to bind to phosphorous and form non-absorbable complexes. Pursuant to the Agreement, Panion has granted Keryx a worldwide (excluding certain Asian-Pacific countries) exclusive license to sublicense, develop, use, sell, import and export ZerenexTM. A copy of such press release is being filed as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(c)

Exhibits

The following exhibit is filed as a part of this report:

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release dated February 15, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Keryx Biopharmaceuticals, Inc.
(Registrant)

Date: February 21, 2006

By: /s/ Ronald C. Renaud, Jr.

Ronald C. Renaud, Jr.
Senior Vice President, Chief Financial Officer,
Secretary and Treasurer

INDEX TO EXHIBITS

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release dated February 15, 2006.
